Mapmygenome

Executive Summary

Mapmygenome is a leading Indian genomics and digital health company that provides at-home DNA testing kits and personalized wellness insights. Founded in 2013 and based in Hyderabad, the company leverages whole-genome sequencing, metagenomic shotgun sequencing of the gut microbiome, DNA-methylation epigenetic clocks, and mitochondrial DNA analysis to deliver comprehensive reports on disease risk, drug response, nutrition, and longevity. Its CAP- and NABL-accredited laboratory ensures high-quality data generation, and the firm augments its reports with certified genetic counseling to translate complex genomic information into actionable health plans. With $40 million raised and a commercial-stage presence, Mapmygenome serves a growing market of preventive health consumers in India, positioning itself at the intersection of genomics, digital health, and personalized medicine. The company's integrated approach and accredited lab differentiate it in the competitive Indian genomics landscape. As awareness of preventive health and pharmacogenomics increases, Mapmygenome is well-positioned to capture market share. Ongoing investments in aging and metabolic health indicate potential for novel product launches. With a strong foundation and clear commercial traction, the company demonstrates significant growth potential in the expanding genomics and wellness sector.

Upcoming Catalysts (preview)

• Q4 2026Launch of advanced aging and longevity panel combining epigenetic clocks and microbiome data80% success
• Q2 2027Strategic partnership with a major Indian hospital chain for integrated genomics-based preventive health programs70% success
• Q3 2027Regulatory clearance for pharmacogenomics test as a Category A medical device in India65% success